19:50 EST Karyopharm (KPTI) trading halted, news pending
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPTI:
- Karyopharm implementing 1-for-15 reverse stock split
- Karyopharm Therapeutics: Hold Rating Maintained Amid Revenue Stagnation and Competitive Pressures
- Karyopharm’s Earnings Call: Growth Amid Financial Challenges
- Karyopharm Therapeutics: Strong Financial Performance and Strategic Developments Justify Buy Rating
- Karyopharm Therapeutics Faces Financial Uncertainty Amid $1.6 Billion Deficit and Urgent Need for Funding